AstraZeneca Pharma India is all set to launch Eculizumab (Soliris) in August 2025 in India. Eculizumab (Soliris) is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS) to inhibit complement - mediated thrombotic microangiopathy.
Earlier, the company had received Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Eculizumab concentrate for solution for infusion 300 mg (10mg/ml) (SOLIRIS).
AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.
